1. Home
  2. SCLX vs MREO Comparison

SCLX vs MREO Comparison

Compare SCLX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

N/A

Current Price

$5.86

Market Cap

55.1M

Sector

Health Care

ML Signal

N/A

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

N/A

Current Price

$0.30

Market Cap

50.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCLX
MREO
Founded
2011
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.1M
50.3M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
SCLX
MREO
Price
$5.86
$0.30
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$1.50
AVG Volume (30 Days)
59.5K
4.9M
Earning Date
04-10-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.67
EPS
N/A
N/A
Revenue
$30,253,000.00
$500,000.00
Revenue This Year
$122.52
$5,184.20
Revenue Next Year
$186.30
$55.51
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.20
$0.20
52 Week High
$34.27
$2.37

Technical Indicators

Market Signals
Indicator
SCLX
MREO
Relative Strength Index (RSI) 33.68 45.51
Support Level $5.48 $0.28
Resistance Level $7.77 $0.35
Average True Range (ATR) 0.42 0.03
MACD -0.08 -0.00
Stochastic Oscillator 13.24 28.17

Price Performance

Historical Comparison
SCLX
MREO

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: